Testbiotech warns against disregarding scientific evidence
14 July 2021 / The EU Commission has rejected criticism of its report on plants and New GE (New Genetic Engineering, genome editing). In a letter to Testbiotech, the Commission stated that there were no new risks associated with plants derived from genetically engineered plants compared to conventionally bred plants, as long as no transgenes were inserted. The Commission is directly repeating claims made by industry and affiliated experts that are contrary to existing scientific evidence. Testbiotech is therefore warning against the spread of misinformation and disregard of science.
Scientific publication identifies important cornerstones
9 July 2021 / Experts from environmental authorities in Austria, Germany, Italy, Poland and Switzerland have published a new scientific paper that, for the first time, defines some important initial cornerstones in the environmental risk assessment of plants altered with new genomic techniques (i.e. ‘New GE’ or ‘genome editing’). The authors show that there can be no justification for only risk assessing plants with additionally inserted genes or with extensive genomic changes. Rather, all plants derived from New GE must be subjected to mandatory risk assessment.
Gaps in European Food Safety Authority EFSA risk assessment exposed
7 July 2021 / The EU Parliament has again voted with a large majority against further approvals for the import of genetically engineered plants. The resolutions concern genetically engineered maize and soybeans that are resistant to insecticides and several herbicides, such as glyphosate and glufosinate. The resolutions also heavily criticise deficiencies in European Food Safety Authority (EFSA) risk assessment.
Interest in patents is also impacting public debate
25 June 2021 / Testbiotech is today publishing a new report showing the increasing number of patent applications being filed and granted in Europe on so-called gene scissors (new genetic engineering, New GE). The patent landscape is dominated by the ‘Corteva group’ which resulted from a merger of Dow AgroSciences and DuPont/Pioneer. Apart from its own patents, Corteva controls access to many other patents needed by breeders who want to use CRISPR/Cas technology.